Serogroup C Neisseria meningitidis invasive infection: Analysis of the possible vaccination strategies for a mass campaign

Acta Paediatrica, International Journal of Paediatrics

Volumn 99, Issue 11, 2010, Pages 1609-1614

  Chiappini, Elena ^a   Venturini, Elisabetta ^a   Bonsignori, Francesca ^a   Galli, Luisa ^a   De Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Children; Meningitis; Neisseria meningitidis Conjugate vaccine; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG ADMINISTRATION; DRUG EFFICACY; HUMAN; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

CHILD; EUROPE; HUMANS; IMMUNIZATION SCHEDULE; MASS VACCINATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES;

EID: 78649732585     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.01908.x     Document Type: Review

References (54)

1. Granoff DM, Feavers IM, Borrow R. Meningococcal vaccines. in: Plokin SA, Orestein WA, editors. In Vaccines. 4th Ed. Philadelphia: Saunders, 2004; 959-87.
2. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5: 21-30.
3. Healy CM, Baker CJ. The future of meningococcal vaccines. Pediatr Infect Dis J 2005; 24: 175-6.
4. Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM. Population-based analysis of meningococcal disease mortality in United States: 1999-2002. Pediatr Infect Dis J 2006; 25: 191-4.
5. Perrocheau A, Taha MK, Levy-Bruhl D. Epidemiology of invasive meningococcal disease in France in 2003. Euro Surveille 2005; 102: 38-41.
6. De Wals P, Deceuninck G, Buolianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292: 2491-4.
7. Lingappa JR, Al-Rabeat AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9: 665-71.
8. Conterno LO, Heath PT. Seroprotection against serogroup C meningococcal disease. BMJ 2008; 336: 1447-8.
9. Kinlin LM, Jamieson F, Brown EM, Brown S, Rawte P, Dolman S, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009; 27: 1735-40.
10. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009; 28: 220-4.
11. Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008; 15: 1694-8.
12. Siu T, Tang W, Dawar M, Patrick DM. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Can J Public Health 2008; 99: 380-2.
13. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20: 58-67.
14. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: Lessons learned. Expert Rev Vaccines 2006; 5: 851-7.
15. Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26: 4434-45.
16. Hamlin J, Senthilnathan S, Bernstein HH. Update on universal childhood immunizations. Curr Opin Pediatr 2008; 20: 483-9.
17. Larrauri A, Cano R, Garcia M, Mateo SD. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 23: 4097-100.
18. Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, Vázquez JA. Impact of the meningococcal C conjugate vaccine in Spain: An epidemiological and microbiological decision. Euro Surveill 2004; 9: 11-5.
19. Salleras L, Domínguez A, Cardeñosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 2003; 21: 729-33. (Pubitemid 36091988)
20. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: Coverage and initial impact of the campaign. Commun Dis Public Health 2002; 5: 220-5.
21. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001; 37: 34-6.
22. Clarke P, Robinson MJ, Ahmad I, Bedford-Russell AR, Connell JE, Powell PJ, et al. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine. Vaccine 2006; 24: 3273-8.
23. Velentgas P, Bohn RL, Brown JS, Chan KA, Gladowski P, Holick CN, et al. A distributed research network model for post-marketing safety studies: The Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf 2008; 17: 1226-34.
24. Bonanni P, Bechini A, Boccalini A, Pecori L, Graziani G, Balocchini E. Meningococcal C vaccination campaign following an increasing number of reported meningitis cases in Tuscany. V&I News - ECDC Newsletter on Vaccines and Immunization 2006; 1: 3.
25. De Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25: 79-80.
26. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: Observational study. BMJ 2008; 336: 1487-91.
27. Sakou II, Tzanakaki G, Tsolia MN, SioumalaM, Barbouni A, Kyprianou M, et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine 2009; 27: 4408-11.
28. De Wals P, Trottier P, Pépin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: A model-based evaluation. Vaccine 2006; 24: 3500-4.
29. De Wals P, Coudeville L, Trottier P Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis. Vaccine 2007; 25: 5433-40.
30. Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum Vaccin 2007; 3: 59-63.
31. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003; 326: 365-6.
32. McVernon J, MacLennan J, Pollard AJ, Oster P, Wakefield MJ, Danzig L, et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J 2003; 22: 659-61.
33. Davison KL, Ramsay ME, Crowcroft NS, Lieftucht A, Kaczmarski EB, Trotter CL, et al. Estimating the burden of serogroup C meningococcal disease in England and Wales. Commun Dis Public Health 2002; 5: 213-9.
34. Pereiró I, Díez-Domingo J, Morant A, Gimeno C, Lerma M, San-MartínM, et al. Epidemiological pattern of meningococcal disease in Valencia, Spain. Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine. Scand J Infect Dis 2001; 33: 581-4.
35. Salleras L, Domínguez A, Prats G, Parron I, Muñoz P. Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. J Epidemiol Community Health 2001; 55: 283-7.
36. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197: 737-43.
37. Laribière A, Miremont-Salamé G, Reyre H, Abouelfath A, Liège L, Moore N, et al. Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol 2005; 61: 907-11.
38. Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, Blanchard Rohner G, et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 2009; 127: 134-43.
39. McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002; 21: 747-53.
40. Lakshman R, Jones I, Walker D, McMurtrie K, Shaw L, Race G, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child 2001; 85: 391-7.
41. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184: 377-80.
42. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005; 24: 128-31.
43. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 2000; 283: 2795-80.
44. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183: 160-3.
45. Halperin SA, McDonald J, Samson L, Danzig L, Santos G, Izu A, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: A randomized double-blind study. Clin Invest Med 2002; 25: 243-51.
46. Kitchin N, Southern J, Morris R, Borrow R, Fiquet A, Boisnard F, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009; 27: 5096-102.
47. Southern J, Gelb D, Andrews N, Waight PA, Morris R, Cartwright K, et al. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Hum Vaccin 2006; 2: 237-42.
48. Tejedor JC, Omeñ aca F, García-Sicilia J, Esporrín C, Molina V, Maré s J, et al. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV / HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV / HiB booster at 18 months of age. Pediatr Infect Dis J 2006; 25: 943-5.
49. El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine 2006; 24: 2544-9. (Pubitemid 43290385)
50. Pichichero ME. Meningococcal conjugate vaccine in adolescents and children. Clin Pediatr (Phila) 2005; 44: 479-89.
51. Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002; 70: 4946-54.
52. Snape MD, Maclennan JM, Lockhart S, English M, Yu LM, Moxon RE, et al. Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine. Pediatr Infect Dis J 2009; 28: 92-7.
53. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-7.
54. Thomas HL, Andrews N, Trotter C, Ramsay M, Miller E. Meningococcal C booster not recommended by evidence. BMJ 2008; 337: 367.